Year-in-Review Series: Recent Psychiatric Drug Approvals & Rejections

Richard Louis Price

M. Zachary Price

Diagnostic Dilemmas and Challenging Differential Diagnoses in Neurop…

University of Miami

A. Bure-Reyes

Schizophrenia Awareness Day Series: The Many Etiologies of Schizophr…

2024 Mental Health Awareness Video Series

H. Nasrallah

Insights Into Muscarinic Agonists: A New Antipsychotic Class Potenti…

Jose Rubio

Schizophrenia Round Table - New Developments

Rakesh Jain

Schizophrenia Awareness Day Series: What Causes the Schizophrenia Sy…

2024 Mental Health Awareness Video Series

D. Malaspina

Advances in Early Detection of Psychosis Using Brain Imaging

Daphne Holt

Cannabis and Mental Health

Natania Crane

Clozapine REMS No More? FDA Panel Recommends to Eliminate the Program

Deanna Kelly

R. Love

Targeting the Glutamatergic System in Schizophrenia

Institute of Mental Health Nottingham

J. Kantrowitz

Schizophrenia Awareness Day Series: Improving the Health of People w…

2024 Mental Health Awareness Video Series

A. Young

Sociobiology of Schizophrenia

Dolores Malaspina

Emerging Therapies in Schizophrenia

Donika Hasanaj

Psychosis in Late Life

Beth LaBardi

Schizophrenia Awareness Day Series: Psychosis is Real, so is Recover…

2024 Mental Health Awareness Video Series

S. Chaudhry, A. Weiss

Conference Highlights: Trajectories of Daily Antipsychotic Use and W…

2024 Conference Highlights

T. Hajek

Year-in-Review Series: Cobenfy & The Schizophrenia Pipeline

Stephen Marder

Conference Highlights: Optimizing Pharmacology for People With SMI -…

2024 Conference Highlights

J. M. Meyer

Emerging Cannabis Research and Treatment for Psychiatric Populations

Tony George

Cariprazine: A D2/D3 Partial Agonist

Institute of Mental Health Nottingham

L. Fonticoli